ClinicalTrials.gg
CompletedNCT00660673Updated Dec 2, 2022Results posted

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

A Phase 3 interventional study of Levodopa-Carbidopa Intestinal Gel (LCIG) and CADD-Legacy® 1400 ambulatory infusion pump in Advanced Parkinson's Disease, sponsored by AbbVie. Completed at 61 sites in 11 countries. Open to participants aged 30 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-12-02.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
262
Allocation
Not applicable
Ages
30 Years to 99 Years
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Parkinson Disease by AbbVie — 6 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · AbbVie.

Enrollment
6th of 25
262 · median 63
Started
2009
with 1 other
Phase 3
16 of 44
none open now
Registered
4th of 44
by date

Among the 44 studies in Parkinson Disease by AbbVie, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2009, is one of 16 in phase 3, and was the 4th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 99 Years · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Parkinson Disease by AbbVie, or all of them as a file.
02

Study summary

The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment (Study S187.3.003 [NCT00360568] or Study S187.3.004 [NCT00335153]).

03

Conditions studied

  • Advanced Parkinson's Disease

Keywords

  • levodopa/carbidopa intestinal gel
  • Severe Motor Fluctuations
  • Levodopa
  • Carbidopa
  • Parkinson's Disease
  • Dyskinesia
04

Who can participate

Ages eligible
30 Years to 99 Years
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant should have completed participation in Study S187.3.003 or S187.3.004; and, in the opinion of the Principal Investigator, would benefit from long-term treatment with LCIG.
  • For Canada, participants will be allowed to participate in the S187.3.005 study with a minimum of 6 months of exposure to LCIG in the S187.3.004 study.
  • The participant must be able to understand the nature of the study and must provide written prior to the conduct of any study related procedures. If the participant does not have the capacity to provide informed consent, full informed consent must be obtained from the participant's legally authorized representative. Consenting will be performed according to local regulations.

Exclusion criteria

Exclusion Criteria:

  • Medical, laboratory, psychiatric, or surgical issues deemed by the investigator to be and which could interfere with the participant's participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
262 participants (actual)

Study arms

  • Experimental
    Levodopa-Carbidopa Intestinal Gel

    Initial dosing is based on the dosing regimen that the participant received during the previous LCIG study. Dosing is individually optimized and can be adjusted at any time during the study as clinically indicated. The total dose/day of LCIG is composed of 3 individually adjusted doses. The morning dose is administered as a bolus infusion, usually 5 to 10 mL (100 to 200 mg levodopa). The maintenance dose is adjustable in steps of 2 mg/hour (0.1 mL/hour), within a range of 1 to 10 mL/hour (20 to 200 mg levodopa/hour) and is usually 2 to 6 mL/hour (40 to 120 mg levodopa/hour). Participants will be allowed to self-administer extra doses of LCIG to address immediate medical needs, normally 0.5 to 2.0 mL. Participants will receive LCIG until it is commercially available.

    Drug: Levodopa-Carbidopa Intestinal Gel (LCIG) · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)

Interventions

  • DrugLevodopa-Carbidopa Intestinal Gel (LCIG)

    LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.

    Also known as: Carbidopa-Levodopa Enteral Suspension (CLES), Duopa®, Duodopa®

  • DeviceCADD-Legacy® 1400 ambulatory infusion pump

    Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.

  • DevicePercutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)

    All participants previously had a PEG-J placed in one of the prior LCIG studies.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) which started on or after the date of the first LCIG Infusion in this study and within 30 days of the date of the last PEG-J exposure. At least possibly drug-related is defined as TEAEs assessed as having a "Possible" or "Probable" or missing relationship to study drug. Serious AEs included any untoward medical occurrence that: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * was a congenital anomaly/birth defect The severity of all AEs was characterized as mild, moderate or severe according to the following definitions: * Mild: usually transient and do not interfere with daily activities. * Moderate: low level of inconvenience or concern to the subject, may interfere with daily activities. * Severe: events interrupt the subject's usual daily activity.

    Time frame: From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).

Secondary outcomes

  1. Number of Participants With Device Complications

    Device complications include complications with the pump, intestinal tube, PEG-J or stoma.

    Time frame: From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days.

  2. Number of Participants With Sleep Attacks

    Participants were asked whether they experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. If yes, participants were asked if they suffered any "bad" outcome or problem from the falling asleep event.

    Time frame: Baseline (final assessment period of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.

  3. Number of Participants With Intense Impulsive Behavior

    To monitor for the development of intense impulsive behavior the Minnesota Impulsive Disorder Interview (MIDI) was administered. The MIDI is a semi-structured clinical interview assessing pathological gambling, trichotillomania, kleptomania, pyromania, intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.

    Time frame: Baseline (final assessment of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.

  4. Number of Participants Who Developed Melanoma

    A comprehensive assessment for the presence of melanoma was performed at least once a year by a dermatologist.

    Time frame: Once per year during the study; median duration of treatment was 1178 days.

  5. Number of Participants With Treatment-emergent Adverse Events of Special Interest (TE AESI)

    Adverse events of special interest (AESIs) were identified using standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQ) or company MedDRA queries (CMQs). The AESI in the following categories were identified on the basis of review of the clinical program and postmarketing observations where the treatment system is commercially available. * Procedure and device associated events * Polyneuropathy, included preferred terms in either the peripheral neuropathy or GuillainBarre syndrome standardized MedDRA query (narrow search), such as polyneuropathy, decreased vibratory sense, peripheral neuropathy, peripheral sensory neuropathy, neuralgia, demyelinating polyneuropathy, and sensory disturbance * Weight loss * Cardiovascular fatalities * Respiratory tract aspiration including aspiration pneumonia/pneumonitis.

    Time frame: From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).

  6. Number of Participants With Any Suicidal Ideation or Behavior

    The Columbia-Suicide Severity Rating Scale (C-SSRS) was implemented with Protocol Amendment 3 (20 March 2012) in order to assess suicidal behavior and ideation. Suicidal ideation includes the wish to be dead, nonspecific active suicidal thoughts, active ideation without intent to act, active ideation with some intent to act, and active ideation with specific plan or intent. Suicidal behavior includes actual attempts, interrupted attempts, aborted attempts, completed suicide, and preparatory acts or behaviors. The number of participants with affirmative responses on the C-SSRS at any time during the treatment period is reported.

    Time frame: Every 6 months (beginning with implementation of Protocol Amendment 3) until final visit; median duration of treatment was 1178 days.

  7. Number of Participants With Potentially Clinically Significant Vital Sign Values

    A vital sign value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.

    Time frame: Baseline and every 6 months until final visit; median duration of treatment was 1178 days.

  8. Number of Participants With Potentially Clinically Significant Hematology Laboratory Values

    A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.

    Time frame: Baseline and every 6 months until final visit; median duration of treatment was 1178 days.

  9. Number of Participants With Potentially Clinically Significant Chemistry Laboratory Values

    A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding baseline value. ULN = upper limit of normal

    Time frame: Baseline and every 6 months until final visit; median duration of treatment was 1178 days.

  10. Number of Participants With Vitamin Levels Outside of the Normal Range

    Special tests for vitamin deficiencies (folic acid, vitamin B6, vitamin B12, methylmalonic acid \[MMA\], and homocysteine) were implemented with Protocol Amendment 2 (27 July 2011). The number of participants with vitamin levels outside of the normal range at any time post-baseline is reported for each vitamin tested.

    Time frame: Every 6 months (beginning with implementation of Protocol Amendment 2) until final visit; median duration of treatment was 1178 days.

  11. Number of Participants Receiving Concomitant Anti-Parkinson's Disease Medications by Treatment Year

    Participants could use oral levodopa-carbidopa for scheduled or supplemental bedtime/overnight doses after the pump was disconnected for the night, or as rescue medication in case of acute deterioration caused by failure of the LCIG system such as tubes and/or the pump or the onset of an acute illness. The initiation of additional concomitant PD medication was allowed at the discretion of the Investigator if medically indicated.

    Time frame: Year 1, Year 2, Year 3, Year 4, Year 5, Year 6, Year 7, Year 8, Year 9, Year 10, > Year 10 (maximum time on treatment was approximately 11.5 years).

  12. Change in Average Daily "Off" Time Based on the Parkinson's Disease Symptom Diary at End of Treatment

    The PD symptom diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "Off" time was defined as time when medication had worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A negative change for "off" time indicates improvement. The PD diary assessment was implemented with Protocol amendment 4 (December 2013) for participants at United States (US) sites only.

    Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

  13. Change in Average Daily "On" Time Without Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment

    The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Non-troublesome dyskinesia does not interfere with function or cause meaningful discomfort. "On" time without troublesome dyskinesia is the sum of "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement. The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

    Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

  14. Change in Average Daily "On" Time With Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment

    The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Troublesome dyskinesia interferes with function or causes meaningful discomfort. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement. The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

    Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

  15. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at End of Treatment

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

    Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

  16. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at End of Treatment

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

    Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

  17. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at End of Treatment

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). UPDRS Part III consists of 14 questions. Questions 20 - 26 are multi-part questions in that they are evaluated separately for multiple body parts. Counting each of these assessments leads to a total of 27 answers for Part III. The UPDRS Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-Point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

    Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

  18. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at End of Treatment

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The UPDRS total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I - III of the scale. The total score ranges from 0 - 176 with 176 representing the worst (total) disability, and 0 no disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

    Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

  19. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at End of Treatment

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias). The UPDRS Part IV Score is the sum of all answers to the 11 questions that comprise Part IV, 4 of which are measured on a 5-point scale (0 - 4) and 7 which are measured on a 2-point scale (0 - 1). The Part IV score ranges from 0 - 23 with higher scores associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

    Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

  20. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Dyskinesia Score at End of Treatment

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias); and The UPDRS Part IV dyskinesia Score is the sum of Questions 32 (What proportion of the waking day are dyskinesias present?), 33 (How disabling are the dyskinesias? ), and 34 (How painful are the dyskinesias?) on UPDRS Part IV, each of which are measured on a 5-point scale (0-4). The Part IV dyskinesia score ranges from 0 - 12 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

    Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

  21. Change in Parkinson's Disease Questionnaire (PDQ-39) Scores at End of Treatment

    The PDQ-39 is a self-administered questionnaire that comprises 39 items addressing the following eight domains of health that patients consider to be adversely affected by the disease: * Mobility (e.g., fear of falling when walking) - 10 questions * Activities of daily living (e.g., difficulty cutting food) - 6 questions * Emotional well-being (e.g., feelings of isolation) - 6 questions * Stigma (e.g., social embarrassment) - 4 questions * Social support - 3 questions * Cognition - 4 questions * Communication - 3 questions * Bodily discomfort - 3 questions Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness. The PDQ-39 summary index (range 0-100) includes responses to all 39 items. A negative change indicates improvement.

    Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

07

Results

Posted Dec 2, 2022

Participant flow

Enrollment began in November 2009 and was completed in October 2012. Participants were enrolled at 61 sites in 11 countries: Australia, Canada, Czech Republic, Israel, New Zealand, Poland, Portugal, the Russian Federation, Thailand, the United Kingdom, and the United States.

Participant flow — Overall Study
MilestoneLevodopa-Carbidopa Intestinal Gel
Started262
Completed145
Not completed117
Withdrew: Adverse event84
Withdrew: Lack of efficacy7
Withdrew: Withdrawal by subject22
Withdrew: Administrative2
Withdrew: Protocol violation2

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events

Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) which started on or after the date of the first LCIG Infusion in this study and within 30 days of the date of the last PEG-J exposure. At least possibly drug-related is defined as TEAEs assessed as having a "Possible" or "Probable" or missing relationship to study drug. Serious AEs included any untoward medical occurrence that: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * was a congenital anomaly/birth defect The severity of all AEs was characterized as mild, moderate or severe according to the following definitions: * Mild: usually transient and do not interfere with daily activities. * Moderate: low level of inconvenience or concern to the subject, may interfere with daily activities. * Severe: events interrupt the subject's usual daily activity.

Time frame:
From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsLevodopa-Carbidopa Intestinal Gel
Any treatment-emergent adverse event (TEAE)253
TEAE at least possibly related to study drug219
Serious TEAE159
Severe TEAE152
TEAE leading to premature study discontinuaton82
TEAE leading to death58
SecondaryNumber of Participants With Device Complications

Device complications include complications with the pump, intestinal tube, PEG-J or stoma.

Time frame:
From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days.
Reported as:
Count of participants · Participants
Number of Participants With Device Complications
ParticipantsLevodopa-Carbidopa Intestinal Gel
Any device complication244
Device complication leading to tube replacement183
Device complication with associated adverse event177
Device complication with associated adverse event leading to tube replacement43
SecondaryNumber of Participants With Sleep Attacks

Participants were asked whether they experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. If yes, participants were asked if they suffered any "bad" outcome or problem from the falling asleep event.

Time frame:
Baseline (final assessment period of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Reported as:
Count of participants · Participants
Number of Participants With Sleep Attacks
ParticipantsLevodopa-Carbidopa Intestinal Gel
Baseline: One or more sleep attacks6
Baseline: One or more sleep attacks with a bad outcome0
Post-baseline: One or more sleep attacks27
Post-baseline: One or more sleep attacks with a bad outcome3
SecondaryNumber of Participants With Intense Impulsive Behavior

To monitor for the development of intense impulsive behavior the Minnesota Impulsive Disorder Interview (MIDI) was administered. The MIDI is a semi-structured clinical interview assessing pathological gambling, trichotillomania, kleptomania, pyromania, intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.

Time frame:
Baseline (final assessment of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Reported as:
Count of participants · Participants
Number of Participants With Intense Impulsive Behavior
ParticipantsLevodopa-Carbidopa Intestinal Gel
Baseline: Pathological Gambling1
Baseline: Trichotillomania0
Baseline: Kleptomania0
Baseline: Pyromania0
Baseline: Intermittent Explosive Disorder0
Baseline: Compulsive Buying1
Baseline: Compulsive Sexual Behavior1
Post-baseline: Pathological Gambling1
Post-baseline: Trichotillomania0
Post-baseline: Kleptomania0
Post-baseline: Pyromania0
Post-baseline: Intermittent Explosive Disorder0
Post-baseline: Compulsive Buying2
Post-baseline: Compulsive Sexual Behavior14
SecondaryNumber of Participants Who Developed Melanoma

A comprehensive assessment for the presence of melanoma was performed at least once a year by a dermatologist.

Time frame:
Once per year during the study; median duration of treatment was 1178 days.
Reported as:
Count of participants · Participants
Number of Participants Who Developed Melanoma
ParticipantsLevodopa-Carbidopa Intestinal Gel
Number of Participants Who Developed Melanoma2
SecondaryNumber of Participants With Treatment-emergent Adverse Events of Special Interest (TE AESI)

Adverse events of special interest (AESIs) were identified using standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQ) or company MedDRA queries (CMQs). The AESI in the following categories were identified on the basis of review of the clinical program and postmarketing observations where the treatment system is commercially available. * Procedure and device associated events * Polyneuropathy, included preferred terms in either the peripheral neuropathy or GuillainBarre syndrome standardized MedDRA query (narrow search), such as polyneuropathy, decreased vibratory sense, peripheral neuropathy, peripheral sensory neuropathy, neuralgia, demyelinating polyneuropathy, and sensory disturbance * Weight loss * Cardiovascular fatalities * Respiratory tract aspiration including aspiration pneumonia/pneumonitis.

Time frame:
From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events of Special Interest (TE AESI)
ParticipantsLevodopa-Carbidopa Intestinal Gel
TE AESI related to procedure and device162
TE AESI related to polyneuropathy24
TE AESI related to weight loss53
TE AESI related to cardiovascular fatalities7
TE AESI related to aspiration71
SecondaryNumber of Participants With Any Suicidal Ideation or Behavior

The Columbia-Suicide Severity Rating Scale (C-SSRS) was implemented with Protocol Amendment 3 (20 March 2012) in order to assess suicidal behavior and ideation. Suicidal ideation includes the wish to be dead, nonspecific active suicidal thoughts, active ideation without intent to act, active ideation with some intent to act, and active ideation with specific plan or intent. Suicidal behavior includes actual attempts, interrupted attempts, aborted attempts, completed suicide, and preparatory acts or behaviors. The number of participants with affirmative responses on the C-SSRS at any time during the treatment period is reported.

Time frame:
Every 6 months (beginning with implementation of Protocol Amendment 3) until final visit; median duration of treatment was 1178 days.
Reported as:
Count of participants · Participants
Number of Participants With Any Suicidal Ideation or Behavior
ParticipantsLevodopa-Carbidopa Intestinal Gel
Any suicidal ideation or behavior32
Any suicidal ideation30
Any suicidal behavior6
Non-suicidal self-injurious behavior1
SecondaryNumber of Participants With Potentially Clinically Significant Vital Sign Values

A vital sign value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.

Time frame:
Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Vital Sign Values
ParticipantsLevodopa-Carbidopa Intestinal Gel
Supine Systolic Blood Pressure ≥180 mmHg and > 40 mmHg increase from Baseline6
Supine Systolic Blood Pressure ≤ 90 mmHg and > 30 mmHg decrease from Baseline13
Standing Systolic Blood Pressure ≥ 180 mmHg and > 40 mmHg increase from Baseline1
Standing Systolic Blood Pressure ≤ 90 mmHg and > 30 mmHg decrease from Baseline26
Orthostatic Change in Systolic Blood Pressure Decrease of ≥ 30 mmHg73
Supine Diastolic Blood Pressure ≥ 105 mmHg and > 30 mmHg increase from Baseline2
Supine Diastolic Blood Pressure ≤ 50 mmHg and > 30 mmHg decrease from Baseline6
Standing Diastolic Blood Pressure ≥ 105 mmHg and > 30 mmHg increase from Baseline7
Standing Diastolic Blood Pressure ≤ 50 mmHg and > 30 mmHg decrease from Baseline14
Orthostatic Change in Diastolic Blood Pressure Decrease of ≥ 20 mmHg45
Supine Pulse ≥ 120 bpm and > 30 bpm increase from Baseline0
Supine pulse ≤ 50 bpm and > 30 bpm decrease from Baseline3
Standing pulse ≥ 120 bpm and > 30 bpm increase from Baseline5
Standing pulse ≤ 50 bpm and > 30 bpm decrease from Baseline4
Temperature ≥ 38.3℃ and ≥ 1.1℃ increase from Baseline0
Weight ≥ 7% increase from Baseline36
Weight ≥ 7% decrease from Baseline140
SecondaryNumber of Participants With Potentially Clinically Significant Hematology Laboratory Values

A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.

Time frame:
Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Hematology Laboratory Values
ParticipantsLevodopa-Carbidopa Intestinal Gel
Red blood cells (RBC) < 2.0 × 10^12 cells/L (Female); < 2.5 × 10^12 cells/L (Male)0
Haemoglobin < 90 g/L (Female); < 100 g/L (Male)9
Haematocrit < 30% (Female); < 34% (Male)16
White blood cells (WBC) < 2.8 × 10^9 cells/L3
WBC > 16.0 × 10^9 cells/L2
Absolute neutrophil count < 1.2 × 10^9 cells/L2
Lymphocytes > 80%0
Absolute lymphocyte count < 0.75 × 10^9 cells/L14
Eosinophils > 10%4
Monocytes > 30%1
Platelet count < 95 × 10^9 cells/L2
Platelet count > 700 × 10^9 cells/L0
Mean corpuscular volume (MCV) < 60 fL0
MCV > 120 fL0
SecondaryNumber of Participants With Potentially Clinically Significant Chemistry Laboratory Values

A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding baseline value. ULN = upper limit of normal

Time frame:
Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Chemistry Laboratory Values
ParticipantsLevodopa-Carbidopa Intestinal Gel
Creatinine > 177 µmol/L0
Calcium < 1.75 mmol/L1
Calcium > 3.0 mmol/L0
Total bilirubin > 2 x ULN0
Aspartate aminotransferase (AST) > 3 x ULN0
Alanine aminotransferase (ALT) > 3 x ULN0
Gamma glutamyl-transferase (GGT) > 3 x ULN5
Lactate dehydrogenase (LDH) > 3 x ULN0
Alkaline phosphatase (ALP) > 400 U/L0
Creatine phosphokinase (CPK) > 3 x ULN6
Non-fasting glucose < 2.78 mmol/L4
Non-fasting glucose > 16.0 mmol/L1
Uric acid > 500 µmol/L (Female); > 590 µmol/L (Male)0
Blood urea nitrogen (BUN) > 10.8 mmol/L11
Cholesterol > 12.9 mmol/L0
SecondaryNumber of Participants With Vitamin Levels Outside of the Normal Range

Special tests for vitamin deficiencies (folic acid, vitamin B6, vitamin B12, methylmalonic acid \[MMA\], and homocysteine) were implemented with Protocol Amendment 2 (27 July 2011). The number of participants with vitamin levels outside of the normal range at any time post-baseline is reported for each vitamin tested.

Time frame:
Every 6 months (beginning with implementation of Protocol Amendment 2) until final visit; median duration of treatment was 1178 days.
Reported as:
Count of participants · Participants
Number of Participants With Vitamin Levels Outside of the Normal Range
ParticipantsLevodopa-Carbidopa Intestinal Gel
Vitamin B12 < 148 pmol/L22
Vitamin B12 > 775 pmol/L46
Methylmalonic acid > 0.4 µmol/L65
Homocysteine < 3.7 µmol/L1
Homocysteine > 13.9 µmol/L198
Vitamin B6 < 20 nmol/L155
Vitamin B6 > 125 nmol/L108
Folic acid < 4.5 nmol/L6
SecondaryNumber of Participants Receiving Concomitant Anti-Parkinson's Disease Medications by Treatment Year

Participants could use oral levodopa-carbidopa for scheduled or supplemental bedtime/overnight doses after the pump was disconnected for the night, or as rescue medication in case of acute deterioration caused by failure of the LCIG system such as tubes and/or the pump or the onset of an acute illness. The initiation of additional concomitant PD medication was allowed at the discretion of the Investigator if medically indicated.

Time frame:
Year 1, Year 2, Year 3, Year 4, Year 5, Year 6, Year 7, Year 8, Year 9, Year 10, > Year 10 (maximum time on treatment was approximately 11.5 years).
Reported as:
Count of participants · Participants
Number of Participants Receiving Concomitant Anti-Parkinson's Disease Medications by Treatment Year
ParticipantsYear 1Year 2Year 3Year 4Year 5Year 6Year 7Year 8Year 9Year 10> Year 10
No concomitant PD medications (LCIG only)12610796745238332821178
Concomitant oral levodopa/carbidopa100917455371698541
Other concomitant PD medications363226177522110
SecondaryChange in Average Daily "Off" Time Based on the Parkinson's Disease Symptom Diary at End of Treatment

The PD symptom diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "Off" time was defined as time when medication had worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A negative change for "off" time indicates improvement. The PD diary assessment was implemented with Protocol amendment 4 (December 2013) for participants at United States (US) sites only.

Time frame:
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Reported as:
Mean · hours
Change in Average Daily "Off" Time Based on the Parkinson's Disease Symptom Diary at End of Treatment
hoursLevodopa-Carbidopa Intestinal Gel
Change from initial LCIG infusion-3.97 ± 2.86
Change from Baseline-0.19 ± 2.19
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel · One-sample t-test · p = <0.001
  • Levodopa-Carbidopa Intestinal Gel · One-sample t-test · p = 0.433
SecondaryChange in Average Daily "On" Time Without Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment

The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Non-troublesome dyskinesia does not interfere with function or cause meaningful discomfort. "On" time without troublesome dyskinesia is the sum of "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement. The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

Time frame:
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Reported as:
Mean · hours
Change in Average Daily "On" Time Without Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment
hoursLevodopa-Carbidopa Intestinal Gel
Change from initial LCIG infusion3.86 ± 3.31
Change from Baseline-0.51 ± 3.19
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel · One-sample t-test · p = <0.001
  • Levodopa-Carbidopa Intestinal Gel · One-sample t-test · p = 0.150
SecondaryChange in Average Daily "On" Time With Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment

The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Troublesome dyskinesia interferes with function or causes meaningful discomfort. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement. The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

Time frame:
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Reported as:
Mean · hours
Change in Average Daily "On" Time With Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment
hoursLevodopa-Carbidopa Intestinal Gel
Change from initial LCIG infusion0.12 ± 3.03
Change from Baseline0.70 ± 2.66
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel · One-sample t-test · p = 0.725
  • Levodopa-Carbidopa Intestinal Gel · One-sample t-test · p = 0.019
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at End of Treatment

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

Time frame:
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Reported as:
Mean · score on a scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at End of Treatment
score on a scaleLevodopa-Carbidopa Intestinal Gel
Change from initial LCIG infusion1.51 ± 2.83
Change from Baseline1.46 ± 2.29
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at End of Treatment

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

Time frame:
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Reported as:
Mean · score on a scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at End of Treatment
score on a scaleLevodopa-Carbidopa Intestinal Gel
Change from initial LCIG infusion3.04 ± 7.76
Change from Baseline6.11 ± 5.48
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at End of Treatment

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). UPDRS Part III consists of 14 questions. Questions 20 - 26 are multi-part questions in that they are evaluated separately for multiple body parts. Counting each of these assessments leads to a total of 27 answers for Part III. The UPDRS Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-Point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

Time frame:
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Reported as:
Mean · score on a scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at End of Treatment
score on a scaleLevodopa-Carbidopa Intestinal Gel
Change from initial LCIG infusion4.51 ± 14.71
Change from Baseline9.18 ± 10.63
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at End of Treatment

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The UPDRS total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I - III of the scale. The total score ranges from 0 - 176 with 176 representing the worst (total) disability, and 0 no disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

Time frame:
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Reported as:
Mean · score on a scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at End of Treatment
score on a scaleLevodopa-Carbidopa Intestinal Gel
Change from initial LCIG infusion9.12 ± 20.91
Change from Baseline16.82 ± 15.01
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at End of Treatment

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias). The UPDRS Part IV Score is the sum of all answers to the 11 questions that comprise Part IV, 4 of which are measured on a 5-point scale (0 - 4) and 7 which are measured on a 2-point scale (0 - 1). The Part IV score ranges from 0 - 23 with higher scores associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

Time frame:
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Reported as:
Mean · score on a scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at End of Treatment
score on a scaleLevodopa-Carbidopa Intestinal Gel
Change from initial LCIG infusion-2.27 ± 3.70
Change from Baseline0.77 ± 2.86
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Dyskinesia Score at End of Treatment

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias); and The UPDRS Part IV dyskinesia Score is the sum of Questions 32 (What proportion of the waking day are dyskinesias present?), 33 (How disabling are the dyskinesias? ), and 34 (How painful are the dyskinesias?) on UPDRS Part IV, each of which are measured on a 5-point scale (0-4). The Part IV dyskinesia score ranges from 0 - 12 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.

Time frame:
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Reported as:
Mean · score on a scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Dyskinesia Score at End of Treatment
score on a scaleLevodopa-Carbidopa Intestinal Gel
Change from initial LCIG infusion-0.19 ± 2.55
Change from Baseline0.55 ± 1.86
SecondaryChange in Parkinson's Disease Questionnaire (PDQ-39) Scores at End of Treatment

The PDQ-39 is a self-administered questionnaire that comprises 39 items addressing the following eight domains of health that patients consider to be adversely affected by the disease: * Mobility (e.g., fear of falling when walking) - 10 questions * Activities of daily living (e.g., difficulty cutting food) - 6 questions * Emotional well-being (e.g., feelings of isolation) - 6 questions * Stigma (e.g., social embarrassment) - 4 questions * Social support - 3 questions * Cognition - 4 questions * Communication - 3 questions * Bodily discomfort - 3 questions Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness. The PDQ-39 summary index (range 0-100) includes responses to all 39 items. A negative change indicates improvement.

Time frame:
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Reported as:
Mean · score on a scale
Change in Parkinson's Disease Questionnaire (PDQ-39) Scores at End of Treatment
score on a scaleLevodopa-Carbidopa Intestinal Gel
Summary Index: Change from initial LCIG infusion-1.46 ± 16.98
Summary Index: Change from Baseline6.83 ± 13.14
Mobility Domain: Change from initial LCIG infusion-2.08 ± 27.98
Mobility Domain: Change from Baseline12.01 ± 21.81
Activities of Daily Living Domain: Change from initial LCIG infusion-1.55 ± 28.40
Activities of Daily Living Domain: Change from Baseline9.35 ± 20.40
Emotional Well-Being Domain: Change from initial LCIG infusion-0.58 ± 19.31
Emotional Well-Being Domain: Change from Baseline2.53 ± 16.95
Stigma Domain: Change from initial LCIG infusion-9.50 ± 22.49
Stigma Domain: Change from Baseline-0.18 ± 19.52
Social Support Domain: Change from initial LCIG infusion3.59 ± 19.54
Social Support Domain: Change from Baseline2.25 ± 17.88
Cognition Domain: Change from initial LCIG infusion1.78 ± 19.52
Cognition Domain: Change from Baseline6.56 ± 19.63
Communication Domain: Change from initial LCIG infusion3.19 ± 23.01
Communication Domain: Change from Baseline8.17 ± 19.27
Bodily Discomfort Domain: Change from initial LCIG infusion-4.74 ± 24.61
Bodily Discomfort Domain: Change from Baseline5.64 ± 19.70

Adverse events

Collected over From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, and maximum was 4217 days (11.5 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levodopa-Carbidopa Intestinal Gel59/262 (22.5%)159/262 (60.7%)223/262 (85.1%)
Most frequent serious events
Showing 10 of 234
Most frequent serious events
EventLevodopa-Carbidopa Intestinal Gel
PNEUMONIAInfections and infestations20/262
COMPLICATION OF DEVICE INSERTIONGeneral disorders14/262
DEATHGeneral disorders13/262
FALLInjury, poisoning and procedural complications13/262
POSTOPERATIVE WOUND INFECTIONInfections and infestations9/262
PNEUMONIA ASPIRATIONRespiratory, thoracic and mediastinal disorders9/262
WEIGHT DECREASEDInvestigations8/262
PARKINSON'S DISEASENervous system disorders8/262
DEVICE DISLOCATIONGeneral disorders6/262
ANAEMIABlood and lymphatic system disorders5/262
Most frequent other events
Showing 10 of 35
Most frequent other events
EventLevodopa-Carbidopa Intestinal Gel
VITAMIN B6 DECREASEDInvestigations71/262
BLOOD HOMOCYSTEINE INCREASEDInvestigations59/262
POSTOPERATIVE WOUND INFECTIONInfections and infestations55/262
FALLInjury, poisoning and procedural complications47/262
URINARY TRACT INFECTIONInfections and infestations45/262
EXCESSIVE GRANULATION TISSUESkin and subcutaneous tissue disorders41/262
INCISION SITE ERYTHEMAInjury, poisoning and procedural complications38/262
PROCEDURAL SITE REACTIONInjury, poisoning and procedural complications33/262
NAUSEAGastrointestinal disorders32/262
WEIGHT DECREASEDInvestigations32/262

Baseline characteristics

Age, Continuous
Age, Continuous(years)Levodopa-Carbidopa Intestinal Gel
Mean64.1 ± 8.9
Age, Customized
Age, Customized(Participants)Levodopa-Carbidopa Intestinal Gel
< 65 years133
≥ 65 years129
Sex: Female, Male
Sex: Female, Male(Participants)Levodopa-Carbidopa Intestinal Gel
Female100
Male162
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Levodopa-Carbidopa Intestinal Gel
Hispanic or Latino7
Not Hispanic or Latino255
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Levodopa-Carbidopa Intestinal Gel
American Indian or Alaska Native1
Asian21
Black of African Heritage or African American1
Native Hawaiian or Other Pacific Islander0
White239
08

Study locations

61 sites
  • University of Alabama at Birmingham /ID# 49941
    Birmingham, Alabama 35294, United States
  • The Research Center of Southern California /ID# 49928
    Encinitas, California 92024, United States
  • The Parkinson's & Movement Disorder Institute - Fountain Valley /ID# 49915
    Fountain Valley, California 92708, United States
  • Universtiy of Southern California /ID# 49913
    Los Angeles, California 90033, United States
  • Colorado Neurological Institute /ID# 49927
    Englewood, Colorado 80113, United States
  • Georgetown University Hospital /ID# 49931
    Washington, District of Columbia 20007, United States
  • Bradenton Research Center, Inc /ID# 49929
    Bradenton, Florida 34205, United States
  • Neurologic Consultants, PA /ID# 49918
    Fort Lauderdale, Florida 33308, United States
  • University of Florida - Archer /ID# 49935
    Gainesville, Florida 32610, United States
  • University of Florida /ID# 49922
    Jacksonville, Florida 32209, United States
  • Charlotte Neurological Service /ID# 49916
    Port Charlotte, Florida 33980, United States
  • University of South Florida /ID# 49919
    Tampa, Florida 33612, United States
  • Georgia Regents University /ID# 49938
    Augusta, Georgia 30912, United States
  • Northwestern University Feinberg School of Medicine /ID# 49944
    Chicago, Illinois 60611-2927, United States
  • Rush University Medical Center /ID# 49930
    Chicago, Illinois 60612, United States
  • University of Kentucky Chandler Medical Center /ID# 49940
    Lexington, Kentucky 40536, United States
  • Louisiana State Univ HSC /ID# 49945
    Shreveport, Louisiana 71130, United States
  • Univ Maryland School Medicine /ID# 49934
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University /ID# 49937
    Baltimore, Maryland 21287, United States
  • Washington University-School of Medicine /ID# 49933
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center /ID# 49911
    Omaha, Nebraska 68198, United States
  • North Shore University Hospital /ID# 49932
    Manhasset, New York 11030, United States
  • The Mount Sinai Hospital /ID# 49942
    New York, New York 10029, United States
  • Columbia Univ Medical Center /ID# 49943
    New York, New York 10032-3725, United States
  • Raleigh Neurology Associates /ID# 49923
    Raleigh, North Carolina 27607, United States
  • Wake Forest Univ HS /ID# 49939
    Winston-Salem, North Carolina 27157, United States
  • University of Cincinnati /ID# 49914
    Cincinnati, Ohio 45267-0585, United States
  • Cleveland Clinic Main Campus /ID# 76173
    Cleveland, Ohio 44195, United States
  • University of Vermont Medical Center /ID# 49912
    Burlington, Vermont 05401-1473, United States
  • King County Public Hospital /ID# 49917
    Kirkland, Washington 98034, United States
  • Froedtert Memorial Lutheran Hospital /ID# 49924
    Milwaukee, Wisconsin 53226, United States
  • Westmead Hospital /ID# 50081
    Westmead, New South Wales 2145, Australia
  • Royal Adelaide Hospital /ID# 50083
    Adelaide, South Australia 5000, Australia
  • Austin Hospital /ID# 50082
    Heidelberg, Victoria 3084, Australia
  • University of Alberta /ID# 78476
    Edmonton, Alberta T6G 2B7, Canada
  • Toronto Western Hospital /ID# 75913
    Toronto, Ontario M5T 2S8, Canada
  • CHUM - Notre-Dame Hospital /ID# 74513
    Montréal, Quebec H2X 0A9, Canada
  • Fakultni Nemocnice u Svate Anny /ID# 50085
    Brno, 656 91, Czechia
  • Fakultni nemocnice Hradec Kralove /ID# 50088
    Hradec Králové, 500 05, Czechia
  • Pardubicka krajska nemocnice, a.s.
    Pardubice, 532 03, Czechia
  • Vseobecna fakultni nemocnice v Praze /ID# 50086
    Praha, 128 21, Czechia
  • Fakultni Nemocnice v Motole /ID# 50084
    Praha, 150 06, Czechia
  • Tel Aviv Sourasky Medical Center /ID# 50089
    Tel-Aviv, 64239, Israel
  • Waikato Hospital /ID# 50091
    Hamilton, Waikato 3240, New Zealand
  • Auckland City Hospital /ID# 50093
    Auckland, 1023, New Zealand
  • New Zealand Brain Research Institute/ID# 50090
    Christchurch, 8011, New Zealand
  • Wellington Hospital /ID# 50092
    Wellington, 6021, New Zealand
  • Miejskie Centrum Medyczne im. dr. Karola Jonschera w Lodzi /ID# 50096
    Łódź, Lodzkie 93-113, Poland
  • NZOZ Centrum Medyczne HCP /ID# 50094
    Poznań, Wielkopolskie 61-485, Poland
  • Hospitais da Universidade de Coimbra /ID# 50098
    Coimbra, 3000-075, Portugal
  • Hospital de Santa Maria /ID# 50099
    Lisboa, 1649-035, Portugal
  • Centro Hospitalar Universitario de Sao Joao, EPE /ID# 50101
    Porto, 4200-319, Portugal
  • Scientific Research Medical Complex Your Health /ID# 50104
    Kazan, 420097, Russian Federation
  • Institution of the Russian Academy of Medical Sciences Scientific Centre of Neurology /ID# 50102
    Moscow, 125367, Russian Federation
  • Military Medical Academy n.a. Kirov /ID# 50103
    Saint Petersburg, 194044, Russian Federation
  • I.P. Pavlov First St. Petersburg State Medical University /ID# 50107
    Saint Petersburg, 197022, Russian Federation
  • City Clinical Hospital #40 /ID# 50106
    Saint Petersburg, 197706, Russian Federation
  • King Chulalongkorn Mem Hosp /ID# 50108
    Bangkok, 10330, Thailand
  • Siriraj Hospital /ID# 50109
    Bangkok, 10700, Thailand
  • The Walton Centre NHS Foundation /ID# 50003
    Liverpool, L9 7LJ, United Kingdom
  • National Hospital for Neurology & Neurosurgery
    London, WC1N 3BG, United Kingdom
09

References and documents

Publications

  • Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Mov Disord. 2018 Jul;33(6):928-936. doi: 10.1002/mds.27338. Epub 2018 Mar 23. PubMed 29570853 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2009 to primary completion in Nov 2021, 144 months.

Results were first posted in Dec 2022, 1 year after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 144 months is above that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2008
First posted
Apr 17, 2008
StartActual
Nov 13, 2009
Primary completionActual
Nov 30, 2021
CompletionActual
Nov 30, 2021
Results first posted
Dec 2, 2022
Last update
Dec 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00660673
Lead sponsor
AbbVie
Collaborators
IQVIA, formerly Quintiles
Responsible party
Sponsor
First posted
Apr 17, 2008
Start date
Nov 13, 2009
Primary completion
Nov 30, 2021
Completion
Nov 30, 2021
Results posted
Dec 2, 2022
Last update
Dec 2, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion